BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31597851)

  • 1. [Management of multiple myeloma in the relapsed/refractory patient].
    Tabayashi T
    Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
    Sonneveld P; De Wit E; Moreau P
    Crit Rev Oncol Hematol; 2017 Apr; 112():153-170. PubMed ID: 28325256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
    Dimopoulos MA; Richardson P; Lonial S
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment strategy for relapsed or refractory myeloma according to the new Guidelines].
    Ozaki S
    Rinsho Ketsueki; 2018; 59(10):2178-2188. PubMed ID: 30305524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
    Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
    Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
    Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM
    Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Relapsed/Refractory Multiple Myeloma.
    Neri P; Bahlis NJ; Paba-Prada C; Richardson P
    Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.
    Nishida H; Yamada T
    J Oncol; 2019; 2019():6084012. PubMed ID: 31781214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice].
    Kuroda J
    Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current treatment of refractory and relapsed multiple myeloma].
    Sasaki M
    Rinsho Ketsueki; 2016; 57(10):2084-2095. PubMed ID: 27795518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
    Moreau P; de Wit E
    Br J Haematol; 2017 Oct; 179(2):198-218. PubMed ID: 28556890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
    Moreau P
    Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment algorithms for multiple myeloma in Japan].
    Ozaki S
    Rinsho Ketsueki; 2017; 58(8):1014-1023. PubMed ID: 28883264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update in treatment options for multiple myeloma in nontransplant eligible patients.
    Broijl A; Sonneveld P
    Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.